

**REMARKS****I. Allowable Claims**

Applicants thank the Office for acknowledging that Claim 5 is allowable.

**II. Rejection of Claims 1 and 2 under 35 USC 102(b) as anticipated by Pfeifer et al.**

A) Claim 1 (and dependent Claim 2 thereon) has been amended to recite that the cell line is one "having endogenous" enzyme activity of the particular type. The cited reference does not teach or reasonably lead one to believe that the cell line of the cited art has the endogenous enzyme activity of the claimed invention, especially where the cited reference teaches away. A mere potential that there may be such activity does not support a finding of anticipation.

B) The claimed invention encompasses an immortalized cell line with particular endogenous characteristics. Claim 1 has been amended to recite that the immortalized human liver cell line has particular "endogenous" enzyme activity. Applicants believe that this clarifies the scope of the claims. The claims as amended should be allowed.

**III. Conclusion**

Reconsideration of the claims as amended in view of the traverse made above is respectfully solicited.

Respectfully submitted,

Dated: May 25, 2006

(847)383-3372

(847)383-3391




Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

**CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 CFR 1.8**  
The undersigned hereby certifies that this paper(s) is(are) being transmitted via facsimile to the Commissioner for Patents, PO Box 1450, Arlington, VA 22313-1450 on this date May 25, 2006, to the Central Fax Number 1-571-273-8300.  
  
Mark Chao, Ph.D., Reg. No. 37,293